MedTrace Logo

A Phase 1 Clinical Study of BW-20805-2-1001 in Healthy Participants

NCT07528053 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2026-04-21

No results posted yet for this study

Summary

A Phase 1 Clinical Study Of BW-20805-2-1001 in Healthy Participants

Conditions

  • HV

Interventions

DRUG

BW-20805-2

Group 3 will receive SC administrations of BW-20805-2 on Day1.

DRUG

BW-20805

Cohort 1 will receive SC administrations of BW-20805 on Day1.

DRUG

BW-20805

Group 2 will receive SC administrations of BW-20805 on Day1

Sponsors & Collaborators

  • Shanghai Argo Biopharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-28
Primary Completion
2026-06-30
Completion
2027-11-05

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07528053 on ClinicalTrials.gov